AssetMemo

Therapeutic area

Nephrology

Glomerulonephritis, chronic kidney disease, polycystic kidney disease, and renal metabolic conditions.

Core & active disease programs

Chronic Kidney Disease
$646.5B+ attributable cost
$50.3B$+ drug spend
97 assets · 2 indications
Provisional & emerging programs (11)Early clinical pipeline & single-asset indications
IgA Nephropathy
5 assets
Primary Membranous Nephropathy
2 assets
APOL1-Mediated Kidney Disease
1 asset
Autosomal Dominant Polycystic Kidney Disease
1 asset
Complement-Mediated Renal Disease
1 asset
Focal Segmental Glomerulosclerosis
1 asset
Glomerular Disease
1 asset
Hemodialysis Access
1 asset
Hyperphosphatemia
1 asset
Kidney Transplant Rejection
1 asset
Lupus Nephritis
1 asset

All assets in Nephrology

← all areas